Changes in coronary vessel resistance during postischemic reperfusion and effectiveness of nitroglycerin.
OBJECTIVE
Microvascular incompetence after ischemia and reperfusion may compromise the normal postischemic coronary perfusion and additionally jeopardize the recovery of the myocytes. We investigated whether such a form of acute endothelial dysfunction occurs in the routine operative setting despite the use of protective measures. For this purpose, we measured pressure-flow relations in the coronary vasculature during heart operations before and after ischemia and after reperfusion and their reaction to the nitric oxide donor nitroglycerin.


METHODS
Forty-eight patients with a low risk profile scheduled for routine coronary artery bypass surgery were included. During normothermic extracorporeal circulation, the fibrillating heart was completely excluded from bypass by clamping of the ascending aorta and snaring of the caval veins. It was relieved of blood by opening the right atrium and venting the left atrium and ventricle to avoid distention. The coronary vessels were perfused under controlled flow, and the perfusion pressures were monitored. This protocol was performed in 24 patients before and immediately after ischemia and after a reperfusion period.


RESULTS
Compared with the preischemic control, vascular resistance was decreased by 17% (P <.003) immediately after ischemia but increased again by 46% (P <.0001) during an average of 25 minutes of reperfusion and, even more important, by 23% (P <.028) in comparison with the preischemic values. In two groups of 12 patients, nitroglycerin was added to the perfusate either in a dosage of 3 microg. kg. min(-1) or as a bolus injection of 2 mg. Low-dose nitroglycerin did not reduce the elevated postreperfusion resistances significantly, but bolus injection did (P <.0002). Coronary vessel resistance increased during reperfusion in particular in patients with a history of hypertension.


CONCLUSIONS
Coronary vasoconstriction during postischemic reperfusion is regularly present in the routine operative setting in cardiac surgery, despite myocardial protection measures. The amount of vasoconstriction varies considerably and is particularly increased in patients with hypertension. The nitric oxide donor nitroglycerin can normalize the elevated resistances, but only in high dosages. This demonstrates a preserved ability of vascular smooth muscle to relax. The phenomenon had no sequelae in our low-risk patients having elective operations. However, it may gain significance in the case of severe left heart hypertrophy and in patients at risk with both a postoperative low-output syndrome and reduced mean arterial pressures during reperfusion.
Kalweit
G A
GA
Department of Thoracic and Cardiovascular Surgery and Institute of Experimental Surgery, Heinrich-Heine-University, Düsseldorf, Germany.
Schipke
J D
JD
Godehardt
E
E
Gams
E
E
D000368:Aged; D002314:Cardioplegic Solutions; D016022:Case-Control Studies; D001026:Coronary Artery Bypass; D003331:Coronary Vessels / Q000503:physiopathology*; D005260:Female; D006439:Hemodynamics / Q000502:physiology; D006801:Humans; D008297:Male; D015425:Myocardial Reperfusion; D015428:Myocardial Reperfusion Injury / Q000503:physiopathology*; D020030:Nitric Oxide Donors / Q000627:therapeutic use*; D005996:Nitroglycerin / Q000627:therapeutic use*; D010477:Perfusion; D017680:Potassium Compounds; D011446:Prospective Studies; D014655:Vascular Resistance / Q000502:physiology*; D014665:Vasodilator Agents / Q000627:therapeutic use*
D002314:Cardioplegic Solutions; D020030:Nitric Oxide Donors; D017680:Potassium Compounds; D014665:Vasodilator Agents; C018369:potassium cardioplegic solution; D005996:Nitroglycerin